The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome
- PMID: 29973279
- PMCID: PMC6030772
- DOI: 10.1186/s40478-018-0559-4
The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome
Abstract
While post mortem studies have identified the major cell types and functional systems affected in Alzheimer's disease (AD) the initial sites and molecular characteristics of pathology are still unclear. Because individuals with Down syndrome (DS) (trisomy 21) develop the full pathological changes of AD in a predictable way by the time they reach middle to late age, a study of the brains of such persons at different ages makes an ideal 'model system' in which the sites of earliest onset of pathology can be detected and the subsequent progression of changes be monitored. In the present study we have examined the brains of 56 individuals with DS ranging from new-born to 76 years for the presence of amyloid and tau pathology in key cortical and subcortical regions. Amyloid pathology was found to commence in the late teens to twenties as a deposition of diffuse plaques initially within the temporal neocortex, quickly involving other neocortical regions but only reaching subcortical regions and cerebellum by the late forties. Cerebral amyloid angiopathy did not regularly commence until after 45-50 years of age. Tau pathology usually commenced after 35 years of age, initially involving not only entorhinal areas and hippocampus but also subcortical regions such as locus caeruleus (LC) and dorsal raphe nucleus (DRN). Later, tau pathology spread throughout the neocortex reaching occipital lobes in most instances by mid-50 years of age. Such a pattern of spread is consistent with that seen in typical AD. We found no evidence that tau pathology might commence within the brain in DS before amyloid deposition had occurred, but there was limited data that suggests tau pathology in LC or DRN might predate that in entorhinal areas and hippocampus or at least be coincident.
Keywords: Alzheimer’s disease; Amyloid; Down syndrome; Tau.
Conflict of interest statement
Ethics approval and consent to participate
The study was approved by Manchester Brain Bank Management Committee (REC reference 09/H0906/52 + 5). Under conditions agreed with the Research Ethics Committee, The Manchester Brain Bank can supply tissue or data to researchers, without requirement for researchers to apply individually to the REC for approval.
Consent for publication
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures


Similar articles
-
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.Brain. 2015 May;138(Pt 5):1370-81. doi: 10.1093/brain/awv050. Epub 2015 Mar 23. Brain. 2015. PMID: 25805643 Free PMC article.
-
Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.Brain. 2018 Jan 1;141(1):271-287. doi: 10.1093/brain/awx320. Brain. 2018. PMID: 29228201 Free PMC article. Clinical Trial.
-
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.Am J Pathol. 2000 Feb;156(2):489-99. doi: 10.1016/S0002-9440(10)64753-0. Am J Pathol. 2000. PMID: 10666378 Free PMC article.
-
The relationship between subcortical tau pathology and Alzheimer's disease.Biochem Soc Trans. 2012 Aug;40(4):711-5. doi: 10.1042/BST20120034. Biochem Soc Trans. 2012. PMID: 22817721 Review.
-
Neuropathology of Alzheimer's Disease.Neurotherapeutics. 2022 Jan;19(1):173-185. doi: 10.1007/s13311-021-01146-y. Epub 2021 Nov 2. Neurotherapeutics. 2022. PMID: 34729690 Free PMC article. Review.
Cited by
-
Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome.Acta Neuropathol Commun. 2021 Dec 27;9(1):201. doi: 10.1186/s40478-021-01298-0. Acta Neuropathol Commun. 2021. PMID: 34961556 Free PMC article.
-
Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome.Acta Neuropathol Commun. 2022 Jun 8;10(1):86. doi: 10.1186/s40478-022-01385-w. Acta Neuropathol Commun. 2022. PMID: 35676735 Free PMC article.
-
Postnatal Cytoarchitecture and Neurochemical Hippocampal Dysfunction in Down Syndrome.J Clin Med. 2021 Jul 31;10(15):3414. doi: 10.3390/jcm10153414. J Clin Med. 2021. PMID: 34362198 Free PMC article.
-
Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.Dev Neurobiol. 2019 Jul;79(7):684-698. doi: 10.1002/dneu.22715. Epub 2019 Sep 11. Dev Neurobiol. 2019. PMID: 31389176 Free PMC article.
-
Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study.Alzheimers Dement. 2025 Mar;21(3):e70071. doi: 10.1002/alz.70071. Alzheimers Dement. 2025. PMID: 40145416 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical